Vascular Endothelial Growth Factor (VEGF)-A is a key regulator of angiogenesis and vascular permeability. It activates VEGFR1-3 on endothelial cells, thereby promoting tumor growth, cell survival, and increased vessel permeability to meet the tumor’s metabolic demands. VEGF-A is also elevated in conditions like diabetic retinopathy and macular edema. Anti-VEGF drugs such as bevacizumab and aflibercept bind VEGF-A, blocking receptor interaction and preventing VEGFR-2 dimerization and downstream signaling. This inhibits endothelial cell proliferation and vascular leakage, suppressing both angiogenesis and tumor growth.

PathHunter KDR/KDR Cell Line models this molecular MOA in a simple, homogenous format, suitable for screening, target validation, characterization, rank ordering, and potency applications. The assay is also available in a ready-to-use bioassay format for lot-release programs.